BACKGROUND: The antiproteinuric pharmacokinetics of Ramipril in response to different doses and modalities of administration has been poorly investigated so far. STUDY DESIGN: Prospective, open-label and not placebo controlled study. SETTING AND PARTICIPANTS: 40 Caucasian adult patients having GFR >/= 50 mL/min, proteinuria 1-3 g/day; SBP/DBP
How to improve duration and efficiency of the antiproteinuric response to Ramipril: RamiPROT-a prospective cohort study
Fuiano G;FOTI D
2017-01-01
Abstract
BACKGROUND: The antiproteinuric pharmacokinetics of Ramipril in response to different doses and modalities of administration has been poorly investigated so far. STUDY DESIGN: Prospective, open-label and not placebo controlled study. SETTING AND PARTICIPANTS: 40 Caucasian adult patients having GFR >/= 50 mL/min, proteinuria 1-3 g/day; SBP/DBPFile in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
